# Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

> **NCT06268574** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ryvu Therapeutics SA** · enrollment: 94 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- High-risk Myelodysplastic Syndrome

## Interventions

- **DRUG:** RVU120

## Key facts

- **NCT ID:** NCT06268574
- **Lead sponsor:** Ryvu Therapeutics SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-23
- **Primary completion:** 2026-02
- **Final completion:** 2026-09
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06268574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06268574, "Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06268574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*